Molnar, David
Knuuti, Juhani
Bax, Jeroen J.
Saraste, Antti
Maaniitty, Teemu
Funding for this research was provided by:
University of Turku
Article History
Received: 4 July 2025
Accepted: 7 January 2026
First Online: 19 January 2026
Declarations
:
: The study was funded by the Finnish Foundation for Cardiovascular Research, Finnish State Research Funding, and the Research Council of Finland. Cleerly, Inc. performed the image analysis without costs and provided an unrestricted research grant for the University of Turku. Dr. Molnar’s work has been co-funded by the European Union’s Horizon Europe Framework program for research and innovation 2021-2027 under the Marie Slodowska-Curie grant agreement No. 101126611, the Swedish Medical Society, the Swedish Heart-Lung Foundation, the Swedish Heart Union and the Gothenburg Medical Society. Dr. Knuuti received consultancy fees from GE Healthcare and Synektik and speaker fees from Bayer, Lundbeck, Boehringer-Ingelheim, Pfizer and Siemens, outside of the submitted work. Dr. Bax received speaker fees from Abbott, outside of the submitted work. Dr. Saraste received consultancy fees from Astra Zeneca, Novo Nordisk and Pfizer, and speaker fees from Abbott, Astra Zeneca, BMS, Janssen, and Pfizer outside of the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.